Journals / Genel Tıp Dergisi / 2011 / Cilt: 21 - Sayı: 2

Improvement of risperidone-induced hyperprolactinemia with the addition of aripiprazole

Risperidona bağlı gelişen hiperprolaktineminin tedaviye aripiprazol eklenmesiyle düzelmesi

Pages
65–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Addition of aripiprazole to treatment may be considered as a first option in cases significant improvement in psychotic symptoms with hyperprolactinemia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hyperprolactinemia is an important side effect of antipsychotic treatment.
📊
Key Findings & Data:All of typical antipsychotics and atypical antipsychotics such as risperidone and amisulpiride have been shown to cause marked elevation in serum prolactin levels, whereas most other atypical antipsychotics such as quetiapine, olanzapine, clozapine, ziprasidone and aripiprazole appear to have little or no affect on serum prolactin levels.
💡
Conclusion & Impact:Conclusion: Addition of aripiprazole to treatment may be considered as a first option in cases significant improvement in psychotic symptoms with hyperprolactinemia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Hyperprolactinemia is an important side effect of antipsychotic treatment. All of typical antipsychotics and atypical antipsychotics such as risperidone and amisulpiride have been shown to cause marked elevation in serum prolactin levels, whereas most other atypical antipsychotics such as quetiapine, olanzapine, clozapine, ziprasidone and aripiprazole appear to have little or no affect on serum prolactin levels. Hyperprolactinemia can lead to gynecomastia, galactorrhea, sexual dysfunction, infertility, oligomenorrhea and amenorrhea. It also reduces the bone mineral density contributes to osteoporosis in a long term. These important side effects cause patients in remission not to continue treatment. Case Report: We report two clinical cases treatment of risperidone-induced hyperprolactinemia and amenorrhea by the partial dopamine agonist aripiprazol induces prolactine normalization. Conclusion: Addition of aripiprazole to treatment may be considered as a first option in cases significant improvement in psychotic symptoms with hyperprolactinemia.

Özet

Amaç: Hiperprolaktinemi antipsikotik tedavisinin önemli bir yan etkisidir. Tipik antipsikotiklerin hepsi ve atipik antipsikotiklerden risperidon ve amisülpiridin serum prolaktin seviyesini yükselttiği bilinmektedir. Atipik antipsikotiklerden ketiapin, olanzapin, klozapin, ziprasidon ve aripiprazolün serum prolaktin düzeylerini çok az ya da hiç yükseltmediği ileri sürülmektedir. Hiperprolaktinemi jinekomasti, galaktore, cinsel işlev bozukluğu, infertilite, oligomenore ve amenoreye neden olmaktadır. Ayrıca kemik mineral yoğunluğunu azaltarak osteoporoza yol açmaktadır. Bu önemli yan etkiler, remisyona girmiş hastaların tedaviye devam etmesinde sorun oluşturmaktadır. Olgu Sunumu: Risperidon ile yanıt alınmış ancak hiperprolaktinemi ve buna bağlı amenore gelişmiş iki hastanın tedavisine aripiprazol eklenmesiyle prolaktin seviyelerinin düşmesi anlatılmıştır. Sonuç: Psikotik belirtilerde belirgin düzelme olup hiperprolaktinemi gelişen olgularda tedaviye aripiprazol eklenmesi ilk seçenek olarak düşünülebilir.

🔖

Cite This Article

AYHAN, M. G., UĞUZ, F., KAYA, N. (2011). Improvement of risperidone-induced hyperprolactinemia with the addition of aripiprazole. Genel Tıp Dergisi, Cilt: 21 - Sayı: 2, 65–69. https://ajindex.com/articles/210373

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Torre D, Falorni A, Pharmacological causes of hyperprolactinemia, Therapeutics and Clinical Risk Management 2007;3:929-51
  2. Öztürk O, Uluşahin A. Ruh Sağlığı ve Bozuklukları. Ruhsal Bozukluklarda İlaç Sağaltımı, 2. cilt, on birinci baskı, Ankara, Nobel Tıp Kitabevleri, 2008
  3. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28:97-100
  4. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch R. Predominant role of the 9- hydroxy metabolite of risperidonein elevating blood prolactin levels. Am J Psychiatry 2005;162:1010–2
  5. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinol 2003;28:109-23
  6. Schotte A, Janssen PFM, Gommeren W. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacol, 1996;124:57- 73
  7. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia J Psychopharmacol 2008;22:46
  8. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607-18
  9. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085- 96
  10. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156:294-8
  11. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64:761-6
  12. Lee BH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Neuro- Psychopharmacol & Biol Psychiatry 2006;30:714–7
  13. Fitzgerald P, Timothy G Dinan Prolactin and dopamine: What is the connection? A Review. J Psychopharmacol 2008;22:12
  14. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: A double blind and randomized study. Psychopharmacology 2005;178:35-40
  15. Kinon